Lakefront Biotherapeutics (LKFT) Non-cash Items (2016 - 2017)
Lakefront Biotherapeutics (LKFT) posted quarterly Non-cash Items of -$34.8 billion for Q2 2017, down 779737.71% year-on-year from N/an in Q2 2016, and down 324955.03% on a QoQ basis from -$10.7 million in Q1 2017.
Lakefront Biotherapeutics (LKFT) Non-cash Items (2016 - 2017) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Non-cash Items for 2 consecutive years, with -$34.8 billion the latest figure, recorded in Q2 2017.
- Quarterly Non-cash Items fell 779737.71% year-over-year to -$34.8 billion in Q2 2017, while the trailing twelve-month figure through Jun 2017 was -$34.8 billion (changed N/A YoY) and the FY2016 annual result came in at $7.5 million, up 106.37% from the prior year.
- Non-cash Items fell to -$34.8 billion in Q2 2017 per LKFT's latest filing, from -$10.7 million in the prior quarter.
- Over the last five years, Non-cash Items for LKFT reached as high as -$4.5 million in Q2 2016 and fell as low as -$34.8 billion in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Lakefront Biotherapeutics | 1.86 Bn | -1.54 Bn | 1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -34.80 Bn |
| Jun 30, 2017 | -34.80 Bn |
| Mar 31, 2017 | -10.71 Mn |
| Mar 31, 2017 | -10.71 Mn |
| Jun 30, 2016 | -4.46 Mn |
| Jun 30, 2016 | -4.46 Mn |
| Mar 31, 2016 | -21.95 Mn |
| Mar 31, 2016 | -21.95 Mn |